Efficacy and safety of celecoxib on the incidence of recurrent colorectal adenomas: a systematic review and meta-analysis
Background: Celecoxib has previously been shown to be effective in reducing recurrent colorectal adenomas, but its long-term effects are unknown. In addition, safety issues are of major concern. Therefore, we examined the efficacy and safety of celecoxib as a chemopreventive agent along with its pos...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2019
|
| Online Access: | http://psasir.upm.edu.my/id/eprint/79637/1/Efficacy%20and%20safety%20of%20celecoxib%20on%20the%20incidence%20of%20recurrent%20colorectal%20adenomas.pdf |
| _version_ | 1796980648127234048 |
|---|---|
| author | Veettil, Sajesh Kalkandi Nathisuwan, Surakit Ching, Siew Mooi Jinatongthai, Peerawat Lim, Kean Ghee Kew, Siang Tong Chaiyakunapruk, Nathorn |
| author_facet | Veettil, Sajesh Kalkandi Nathisuwan, Surakit Ching, Siew Mooi Jinatongthai, Peerawat Lim, Kean Ghee Kew, Siang Tong Chaiyakunapruk, Nathorn |
| author_sort | Veettil, Sajesh Kalkandi |
| collection | UPM |
| description | Background: Celecoxib has previously been shown to be effective in reducing recurrent colorectal adenomas, but its long-term effects are unknown. In addition, safety issues are of major concern. Therefore, we examined the efficacy and safety of celecoxib as a chemopreventive agent along with its posttreatment effect. Methods: We performed a meta-analysis based on a systematic review of randomized controlled trials (RCTs) comparing celecoxib at various doses (400 mg once daily, 200 mg twice daily, and 400 mg twice daily) vs placebo in persons with history of colorectal adenomas. Several databases were searched from inception up to April 2018. Long-term follow-ups of RCTs were also included to evaluate posttreatment effect. Primary outcome was the incidence of recurrent colorectal adenomas. Various safety outcomes were evaluated, especially cardiovascular (CV) events. Risk-benefit integrated analyses were also performed. Results: A total of three RCTs (4,420 patients) and three post-trial studies (2,159 patients) were included in the analysis. Use of celecoxib at any dose for 1-3 years significantly reduced the incidence of recurrent advanced adenomas (risk ratio, 0.42 [95% CI, 0.34-0.53]) and any adenomas (0.67 [95% CI, 0.62-0.72]) compared with placebo. Subgroup analysis on different dosing suggested a greater effect with 400 mg twice daily. However, celecoxib 400 mg twice daily significantly increased the risk of serious adverse (1.2 [95% CI, 1.0-1.5]) and CV events (3.42 [95% CI, 1.56-7.46]), while celecoxib at 400 mg/day, especially with once daily dosing, did not increase CV risk (1.01 [95% CI, 0.70-1.46]). Analysis of post-trial studies indicated that the treatment effect disappeared (1.15 [95% CI, 0.88-1.49]) after discontinuing celecoxib for >2 years. Conclusion: Celecoxib 400 mg once daily dosing could potentially be considered as a viable chemopreventive option in patients with high risk of adenomas but with low CV risk. Long-term trials on celecoxib at a dose of ≤400 mg either once or twice daily are warranted. |
| first_indexed | 2024-03-06T10:26:08Z |
| format | Article |
| id | upm.eprints-79637 |
| institution | Universiti Putra Malaysia |
| language | English |
| last_indexed | 2024-03-06T10:26:08Z |
| publishDate | 2019 |
| publisher | Dove Medical Press |
| record_format | dspace |
| spelling | upm.eprints-796372021-08-19T00:34:36Z http://psasir.upm.edu.my/id/eprint/79637/ Efficacy and safety of celecoxib on the incidence of recurrent colorectal adenomas: a systematic review and meta-analysis Veettil, Sajesh Kalkandi Nathisuwan, Surakit Ching, Siew Mooi Jinatongthai, Peerawat Lim, Kean Ghee Kew, Siang Tong Chaiyakunapruk, Nathorn Background: Celecoxib has previously been shown to be effective in reducing recurrent colorectal adenomas, but its long-term effects are unknown. In addition, safety issues are of major concern. Therefore, we examined the efficacy and safety of celecoxib as a chemopreventive agent along with its posttreatment effect. Methods: We performed a meta-analysis based on a systematic review of randomized controlled trials (RCTs) comparing celecoxib at various doses (400 mg once daily, 200 mg twice daily, and 400 mg twice daily) vs placebo in persons with history of colorectal adenomas. Several databases were searched from inception up to April 2018. Long-term follow-ups of RCTs were also included to evaluate posttreatment effect. Primary outcome was the incidence of recurrent colorectal adenomas. Various safety outcomes were evaluated, especially cardiovascular (CV) events. Risk-benefit integrated analyses were also performed. Results: A total of three RCTs (4,420 patients) and three post-trial studies (2,159 patients) were included in the analysis. Use of celecoxib at any dose for 1-3 years significantly reduced the incidence of recurrent advanced adenomas (risk ratio, 0.42 [95% CI, 0.34-0.53]) and any adenomas (0.67 [95% CI, 0.62-0.72]) compared with placebo. Subgroup analysis on different dosing suggested a greater effect with 400 mg twice daily. However, celecoxib 400 mg twice daily significantly increased the risk of serious adverse (1.2 [95% CI, 1.0-1.5]) and CV events (3.42 [95% CI, 1.56-7.46]), while celecoxib at 400 mg/day, especially with once daily dosing, did not increase CV risk (1.01 [95% CI, 0.70-1.46]). Analysis of post-trial studies indicated that the treatment effect disappeared (1.15 [95% CI, 0.88-1.49]) after discontinuing celecoxib for >2 years. Conclusion: Celecoxib 400 mg once daily dosing could potentially be considered as a viable chemopreventive option in patients with high risk of adenomas but with low CV risk. Long-term trials on celecoxib at a dose of ≤400 mg either once or twice daily are warranted. Dove Medical Press 2019 Article PeerReviewed text en http://psasir.upm.edu.my/id/eprint/79637/1/Efficacy%20and%20safety%20of%20celecoxib%20on%20the%20incidence%20of%20recurrent%20colorectal%20adenomas.pdf Veettil, Sajesh Kalkandi and Nathisuwan, Surakit and Ching, Siew Mooi and Jinatongthai, Peerawat and Lim, Kean Ghee and Kew, Siang Tong and Chaiyakunapruk, Nathorn (2019) Efficacy and safety of celecoxib on the incidence of recurrent colorectal adenomas: a systematic review and meta-analysis. Cancer Management and Research, 2019 (11). pp. 561-571. ISSN 1179-1322 https://www.dovepress.com/efficacy-and-safety-of-celecoxib-on-the-incidence-of-recurrent-colorec-peer-reviewed-fulltext-article-CMAR 10.2147/CMAR.S180261 |
| spellingShingle | Veettil, Sajesh Kalkandi Nathisuwan, Surakit Ching, Siew Mooi Jinatongthai, Peerawat Lim, Kean Ghee Kew, Siang Tong Chaiyakunapruk, Nathorn Efficacy and safety of celecoxib on the incidence of recurrent colorectal adenomas: a systematic review and meta-analysis |
| title | Efficacy and safety of celecoxib on the incidence of recurrent colorectal adenomas: a systematic review and meta-analysis |
| title_full | Efficacy and safety of celecoxib on the incidence of recurrent colorectal adenomas: a systematic review and meta-analysis |
| title_fullStr | Efficacy and safety of celecoxib on the incidence of recurrent colorectal adenomas: a systematic review and meta-analysis |
| title_full_unstemmed | Efficacy and safety of celecoxib on the incidence of recurrent colorectal adenomas: a systematic review and meta-analysis |
| title_short | Efficacy and safety of celecoxib on the incidence of recurrent colorectal adenomas: a systematic review and meta-analysis |
| title_sort | efficacy and safety of celecoxib on the incidence of recurrent colorectal adenomas a systematic review and meta analysis |
| url | http://psasir.upm.edu.my/id/eprint/79637/1/Efficacy%20and%20safety%20of%20celecoxib%20on%20the%20incidence%20of%20recurrent%20colorectal%20adenomas.pdf |
| work_keys_str_mv | AT veettilsajeshkalkandi efficacyandsafetyofcelecoxibontheincidenceofrecurrentcolorectaladenomasasystematicreviewandmetaanalysis AT nathisuwansurakit efficacyandsafetyofcelecoxibontheincidenceofrecurrentcolorectaladenomasasystematicreviewandmetaanalysis AT chingsiewmooi efficacyandsafetyofcelecoxibontheincidenceofrecurrentcolorectaladenomasasystematicreviewandmetaanalysis AT jinatongthaipeerawat efficacyandsafetyofcelecoxibontheincidenceofrecurrentcolorectaladenomasasystematicreviewandmetaanalysis AT limkeanghee efficacyandsafetyofcelecoxibontheincidenceofrecurrentcolorectaladenomasasystematicreviewandmetaanalysis AT kewsiangtong efficacyandsafetyofcelecoxibontheincidenceofrecurrentcolorectaladenomasasystematicreviewandmetaanalysis AT chaiyakunapruknathorn efficacyandsafetyofcelecoxibontheincidenceofrecurrentcolorectaladenomasasystematicreviewandmetaanalysis |